Literature DB >> 23293324

Stereochemical assignment and anti-inflammatory properties of the omega-3 lipid mediator resolvin E3.

Yosuke Isobe1, Makoto Arita, Ryo Iwamoto, Daisuke Urabe, Hidenori Todoroki, Koji Masuda, Masayuki Inoue, Hiroyuki Arai.   

Abstract

Uncontrolled inflammation is now considered to be a link between many widely occurring diseases. Thus, controlling the innate inflammatory response and its local chemical mediators has been receiving increasing attention. We recently identified a novel family of eicosapentaenoic acid (EPA)-derived mediators produced by eosinophils, denoted as resolvin E3 (RvE3), that possess potent anti-inflammatory actions both in vitro and in vivo. Carbons at 17 and 18 positions are asymmetric and thus the molecule has a total of four potential stereoisomers. Here, we assigned the stereochemistry of the conjugated double bonds and chirality of alcohols present in two natural isomers of RvE3 with four different stereoisomers prepared by total organic synthesis. The complete structures of two natural isomers of RvE3 were determined to be 17R,18S- and 17R,18R-dihydroxy-5Z,8Z,11Z,13E,15E-EPA, respectively. These natural isomers prepared by total organic synthesis displayed a potent anti-inflammatory action by limiting neutrophil infiltrations both in vitro and in vivo. The unnatural stereoisomers were much less active compared with the natural isomers, demonstrating the stereoselective action of RvE3.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23293324     DOI: 10.1093/jb/mvs151

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  23 in total

Review 1.  The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution.

Authors:  Charles N Serhan; Nan Chiang; Jesmond Dalli
Journal:  Semin Immunol       Date:  2015-04-07       Impact factor: 11.130

Review 2.  Specialized Proresolving Mediators in Innate and Adaptive Immune Responses in Airway Diseases.

Authors:  Nandini Krishnamoorthy; Raja-Elie E Abdulnour; Katherine H Walker; Braden D Engstrom; Bruce D Levy
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

3.  Short-term n-3 fatty acid supplementation but not aspirin increases plasma proresolving mediators of inflammation.

Authors:  Anne Barden; Emilie Mas; Kevin D Croft; Michael Phillips; Trevor A Mori
Journal:  J Lipid Res       Date:  2014-09-03       Impact factor: 5.922

Review 4.  Advances in Our Understanding of Oxylipins Derived from Dietary PUFAs.

Authors:  Melissa Gabbs; Shan Leng; Jessay G Devassy; Md Monirujjaman; Harold M Aukema
Journal:  Adv Nutr       Date:  2015-09-15       Impact factor: 8.701

Review 5.  Resolution of acute inflammation in the lung.

Authors:  Bruce D Levy; Charles N Serhan
Journal:  Annu Rev Physiol       Date:  2013-12-02       Impact factor: 19.318

Review 6.  Resolution phase lipid mediators of inflammation: agonists of resolution.

Authors:  Charles N Serhan; Nan Chiang
Journal:  Curr Opin Pharmacol       Date:  2013-06-06       Impact factor: 5.547

Review 7.  Biological and pathophysiological roles of end-products of DHA oxidation.

Authors:  Valentin P Yakubenko; Tatiana V Byzova
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2016-10-03       Impact factor: 4.698

8.  Divergent shifts in lipid mediator profile following supplementation with n-3 docosapentaenoic acid and eicosapentaenoic acid.

Authors:  James F Markworth; Gunveen Kaur; Eliza G Miller; Amy E Larsen; Andrew J Sinclair; Krishna Rao Maddipati; David Cameron-Smith
Journal:  FASEB J       Date:  2016-07-26       Impact factor: 5.191

Review 9.  Pro-resolving lipid mediators are leads for resolution physiology.

Authors:  Charles N Serhan
Journal:  Nature       Date:  2014-06-05       Impact factor: 49.962

10.  Subgingival Microbiome and Specialized Pro-Resolving Lipid Mediator Pathway Profiles Are Correlated in Periodontal Inflammation.

Authors:  Chun-Teh Lee; Ruoxing Li; Lisha Zhu; Gena D Tribble; W Jim Zheng; Brittney Ferguson; Krishna Rao Maddipati; Nikola Angelov; Thomas E Van Dyke
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.